Irbesartan tablets
Main ingredients
The main ingredient of this product is: Irbesartan. Chemical name: 2-butyl-3-[4-[2-(1H-tetrazol-5-yl)phenyl] benzyl]-1,3-diazaspiro-[4.4] non-1-ene -4-keto. Molecular formula: C25H28N6O Molecular weight: 428.54
Functional indications
High blood pressure.
Dosage
oral. The recommended starting dose is 0.15g, once a day. Depending on the condition, it can be increased to 0.3g, once a day. It can be used alone or in combination with other antihypertensive drugs. When severe hypertension and the blood pressure drop is still not satisfactory after drug increase, small doses of diuretics (such as thiazides) or other antihypertensive drugs can be added.
drug interactions
1. When this product is combined with diuretics, attention should be paid to insufficient blood volume or hypotension due to low sodium. When combined with potassium-sparing diuretics (such as triamterene, etc.), an increase in serum potassium should be avoided. 2. There is no obvious interaction between this product and warfarin. 3. Combined use with digitalis drugs such as digoxin, b-blockers such as atenolol, calcium antagonists such as nifedipine, etc. will not affect the pharmacokinetics of each other.
Medication for special populations
Medication for pregnant and lactating women: Medication is prohibited for pregnant and lactating women. Pediatric use: There is no data on the safety of this drug in patients younger than 18 years of age. Medication in the Elderly: Not clear yet.
Precautions
1. Hypovolemia and/or sodium deficiency should be corrected before starting treatment. 2. Patients with renal insufficiency may need to reduce the dose of this product. Also pay attention to changes in blood urea nitrogen, serum creatinine and serum potassium. Changes in renal function may occur in individual sensitive patients as a result of renin-angiotensin-aldosterone suppression. 3. Patients with hepatic insufficiency and elderly patients do not need to adjust the dosage when using this product. 4. Irbesartan cannot be excreted from the body through hemodialysis.
Adverse reactions
Common adverse reactions are: headache, dizziness, palpitations, and occasional cough. They are generally mild and transient, and most patients can tolerate it if they continue to take the medicine. Rarely, urticaria and angioedema occur. Literature reports that the incidence of adverse reactions of this product is greater than 1%: indigestion, heartburn, diarrhea, skeletal muscle pain, fatigue and upper respiratory tract infection, but there is no significant difference compared with the blank control group. The incidence rates were greater than 1% but lower than those in the control group, including abdominal pain, anxiety, nervousness, chest pain, pharyngitis, nausea and vomiting, rash, tachycardia, etc. The incidence of hypotension and orthostatic hypotension is approximately 0.4%.
